A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Genre
Journal articleDate
2022-05-26Author
Landoni, GiovanniPiemonti, Lorenzo
Monforte, Antonella d'Arminio
Grossi, Paolo
Zangrillo, Alberto
Bucci, Enrico

Allegretti, Marcello
Goisis, Giovanni
Gavioli, Elizabeth M.
Patel, Neal
de Pizzol, Maria
Pasedis, Georgea
Mantelli, Flavio
Group
Sbarro Health Research Organization (Temple University)Department
BiologyPermanent link to this record
http://hdl.handle.net/20.500.12613/8083
Metadata
Show full item recordDOI
https://doi.org/10.1007/s40121-022-00644-6Abstract
Acute lung injury and acute respiratory distress syndrome are common complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in patients with COVID-19 are associated with cytokine release syndrome. Binding of interleukin-8 (CXCL8/IL-8) to its chemokine receptors, CXCR1/2, may mediate this inflammatory process. The aim of this clinical trial was to determine if CXCR1/2 blockade with reparixin can improve clinical outcomes in hospitalized patients with severe COVID-19 pneumonia. The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer.Citation
Landoni, G., Piemonti, L., Monforte, A.d. et al. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. Infect Dis Ther 11, 1559–1574 (2022). https://doi.org/10.1007/s40121-022-00644-6Citation to related work
SpringerHas part
Infectious Diseases and Therapy, Vol. 11ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/8055
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC